Movatterモバイル変換


[0]ホーム

URL:


CN109459372A - Erythroblast simulation particle and the preparation method and application thereof - Google Patents

Erythroblast simulation particle and the preparation method and application thereof
Download PDF

Info

Publication number
CN109459372A
CN109459372ACN201811264421.XACN201811264421ACN109459372ACN 109459372 ACN109459372 ACN 109459372ACN 201811264421 ACN201811264421 ACN 201811264421ACN 109459372 ACN109459372 ACN 109459372A
Authority
CN
China
Prior art keywords
erythroblast
cell
preparation
simulation particle
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201811264421.XA
Other languages
Chinese (zh)
Other versions
CN109459372B (en
Inventor
刘旭
蔡清华
王丹凤
林月
朱子是
魏学芹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dirui Medical Technology Co Ltd
Original Assignee
Dirui Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dirui Medical Technology Co LtdfiledCriticalDirui Medical Technology Co Ltd
Priority to CN201811264421.XApriorityCriticalpatent/CN109459372B/en
Publication of CN109459372ApublicationCriticalpatent/CN109459372A/en
Application grantedgrantedCritical
Publication of CN109459372BpublicationCriticalpatent/CN109459372B/en
Activelegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Classifications

Landscapes

Abstract

Erythroblast simulation particle and the preparation method and application thereof, belongs to technical field of medical detection.Solve the problems, such as how to provide a kind of simple process, the preparation method for the erythroblast simulation particle that yield is high, product stability is good.Preparation method of the invention: first separation and Washed Red Blood Cells obtain purification of erythropoietin;Then diluted purification of erythropoietin is used, load agent is added, load agent is introduced into purification of erythropoietin under the action of pulse electromagnetic field;Cell fixer is added into the cell being introduced into after loading agent again, 18-28 DEG C of fixation washs cell, saved with cell-preservation liquid, obtain erythroblast simulation particle.The preparation step is simple, and agents useful for same ingredient is more single, and products collection efficiency obtained is higher, is suitble to a large amount of production.

Description

Erythroblast simulation particle and the preparation method and application thereof
Technical field
The invention belongs to technical field of medical detection, and in particular to a kind of erythroblast simulation particle and preparation method thereofWith application.
Background technique
The mature erythrocyte of normal people does not contain nucleus, and main component is protein and iron, has the energy of transport oxygenPower, erythroblast belong to the initial puerilism during red blood cell development, are generally present in marrow, but some pathology feelingsIt also will appear under condition, in peripheral blood erythroblast (NRBC), the detection to erythroblast in blood of human body, can beThe diagnosis of disease provides foundation.
Its clinical meaning is as follows:
1, hyperplastic anemia: being most commonly in various anaemias, acute posthemorrhagic anemia, megaloblastic anemia, seriousHypochrosis microcytic anemia;It is common to there is metarubricyte or rubricyte;Occurring erythroblast in peripheral blood indicates boneErythron obvious proliferation in marrow;
2, erythremic myelosis, erythroleukemia: erythroneocytosis paraplasm and being released into blood in marrow, with pronormoblast, early childrenRed blood cell is common;
3, extramedullary hematopoiesis: when myelofibrosis, the hematopoiesis function of the organized renewings embryonic stage such as spleen, liver, lymph node, theseFor tissue due to a lack of the ability of regulation and control discharged to haemocyte, inmature haemocyte largely enters peripheral blood;The children of each stage of development is red thinBorn of the same parents are visible, and visible immature granulocyte and megacaryocyte;
4, other: such as metastatic carcinoma of bone marrow, severe depletion of oxygen.
Currently, more and more cellanalyzers have the function of detecting erythroblast, in order to guarantee the standard of measured valueTrue property need to carry out quality control to it, that is, the quality-control product containing erythroblast simulation particle is used to be detected.
United States Patent (USP) US5559037 (Kim et al.) discloses a kind of fluidic cell for erythroblast and leucocyteThe method of analysis of accounts.The method use fluorescence, low angle light scattering and axis light loss mensurations, so as to from white blood sampleTell NRBC.United States Patent (USP) US5879900 (Kim et al.) further discloses a kind of discrimination NRBC, leucocyte and impairedThe method of leucocyte, and the leucocyte difference method for distinguishing in blood sample is provided by flow cytometer, this method lacksPoint is that accuracy is not high.
United States Patent (USP) US7176031 and US6962817 are disclosed using artificial compound particle simulation people's erythroblastMethod.The defect of this method is compound particle, and production process is complex and costly.United States Patent (USP) US7354767 is disclosedThe method for preparing erythroblast simulation particle using general mammalian red blood cell (being free of nucleus).This method preparationSimulation particle and people's erythroblast nucleus size it is close, suitable for the blood using impedance method detection erythroblastCytoanalyze.But this simulation particle is free of nucleus, is unsuitable for simulating people's erythroblast by specific fluorescent dyeingFluorescent characteristic afterwards.Technical solution disclosed in United States Patent (USP) US7195919 is by connecting large biological molecule in erythrocyte surface(such as: nucleic acid, skin chain), can simulate the fluorescent characteristic of people's erythroblast.This method is disadvantageous in that workSkill is complicated, and the large biological molecule higher cost as raw material.
United States Patent (USP) US6723563 and US6653137 propose with birds (such as turkey or chicken), reptiles (such as alligator) orThe red blood cell of fish (such as toadfish) is that raw material prepares erythroblast simulation particle.United States Patent (USP) US6406915, US6403377,US6399388, US6221668 and US6200500 disclose the side that erythroblast simulation particle is prepared using turkey erythrocytesMethod.United States Patent (USP) US6448085 discloses the method for preparing erythroblast simulation particle using chicken red blood cell.United States Patent (USP)US6187590 and US5858790, which is disclosed, prepares erythroblast simulation particle using the red blood cell of turkey, chicken and frog crouching class fishMethod.United States Patent (USP) US7285417, US7135341 and US7198953 disclose that be prepared with core using alligator red blood cell redThe method of cell simulation particle.The common ground of these technical solutions is: use is with nucleolate animal erythrocyte, including birdClass, reptiles and the red blood cell of fish simulate people's erythroblast.This method is disadvantageous in that, most birds,Reptiles and the red blood cell of fish are oval, larger with mankind's erythroblast morphological differences of subcircular.Therefore certainIn the case of, these animal erythroblasts can not simulate the feature of people's erythroblast well.For example, with fluidic cellWhen art detects cell, elliptical erythrocyte is inconsistent by flow chamber direction, thus generates the very big forward direction of difference in sizeScattered light signal, and round or subcircular cell is then not in this situation.
It can be seen that the method for preparing erythroblast simulation particle in the prior art all has certain disadvantage, needA kind of preparation method for the erythroblast simulation particle that simple process, yield are high, product stability is good.
Summary of the invention
In view of this, the purpose of the present invention is how to provide, a kind of simple process, yield are high, product stability is good coreThe preparation method of red blood cell simulation particle, and the erythroblast simulation particle for providing this method preparation is used as with fluorescence-scatteringLight method is the application of the Quality Control object of the cellular blood analyzer of testing principle.
The technical solution that the present invention realizes that above-mentioned purpose is taken is as follows.
The preparation method of erythroblast simulation particle, steps are as follows:
Step 1: separation and Washed Red Blood Cells, obtain purification of erythropoietin;
Step 2: load agent is added, agent will be loaded under the action of pulse electromagnetic field with diluted purification of erythropoietinIt is introduced into purification of erythropoietin;
The load agent is artificial synthesized DNA or RNA segment, and the additive amount for loading agent is greater than 1.5 μ g/L and in 3.0 μWithin g/L;
Step 3: cell fixer is added to being introduced into the cell after load agent, 18-28 DEG C of fixation washs cell, with thinBorn of the same parents save liquid and save, and obtain erythroblast simulation particle.
Preferably, in the step 1, red blood cell is human red blood cells or the MCV mammal similar with human red blood cellsRed blood cell.
Preferably, in the step 2, with diluted purification of erythropoietin to 1012-1014A/L.
Preferably, in the step 2, the pH value of dilution is 7.1-7.5, by ATP, MgCl2、KH2PO4、NaHCO3、Glucose and water composition, the concentration of ATP are 0.1%-1.0%, MgCl2Concentration be 0.1%-0.5%, KH2PO4Concentration is0.5%-3.0%, NaHCO3Concentration is 0.05%-0.3%, the concentration 0.01%-0.1% of glucose.
Preferably, in the step 2, load agent will be introduced into purification of erythropoietin under the action of pulse electromagnetic fieldProcess are as follows: electroporation apparatus 90-120V voltage stimulate 4-8 seconds.
Preferably, in the step 1 and step 3, the detergent for washing use includes buffer, preservative, inorganicSalt and water.
Preferably, in the step 3, cell fixer includes fixative, buffer, disodium ethylene diamine tetraacetate(EDTA-2Na), preservative and water;Fixative is one of formaldehyde, acetaldehyde, glutaraldehyde, paraformaldehyde, methanol, acetone or moreKind;Set time is 3-5h.
Preferably, in the step 3, cell-preservation liquid includes buffer, nutritional ingredient, preservative and water.
The present invention also provides the erythroblast simulation particles of the preparation method of above-mentioned erythroblast simulation particle preparation.
The present invention also provides above-mentioned erythroblast simulation particles as using nucleic acid fluorescent dyeing as the blood of testing principleThe application of the Quality Control object of cytoanalyze.
Compared with prior art, the invention has the benefit that
The preparation method of erythroblast simulation particle of the invention, by nucleic acid object by way of electric pulse stimulation cellMatter introduce mature erythrocyte in prepare erythroblast simulation particle, the simulation particle preparation step is simple, agents useful for same atPoint more single, products collection efficiency obtained is higher, is suitble to a large amount of production.
Detailed description of the invention
The erythroblast simulation particle that nucleic acid substances are introduced without electric pulse stimulation cell is shown in Fig. 1, with maturationThe whole blood quality control materials of red blood cell analogies 1:4 mixed preparing blood analyser in mass ratio is being inspection with nucleic acid fluorescent dyeingIt surveys on the blood cell analyzer of principle and tests picture (erythroblast channel is only provided).
Erythroblast simulation particle prepared by embodiment 1 is shown in Fig. 2, presses quality with mature erythrocyte analogiesThan the whole blood quality control materials of 1:4 mixed preparing blood analyser, using nucleic acid fluorescent dyeing as the blood cell of testing principle pointPicture is tested in analyzer (erythroblast channel is only provided).
Erythroblast simulation particle prepared by embodiment 2 is shown in Fig. 3, presses quality with mature erythrocyte analogiesThan the whole blood quality control materials of 1:4 mixed preparing blood analyser, using nucleic acid fluorescent dyeing as the blood cell of testing principle pointPicture is tested in analyzer (erythroblast channel is only provided).
Erythroblast simulation particle prepared by embodiment 3 is shown in Fig. 4, presses quality with mature erythrocyte analogiesThan the whole blood quality control materials of 1:4 mixed preparing blood analyser, using nucleic acid fluorescent dyeing as the blood cell of testing principle pointPicture is tested in analyzer (erythroblast channel is only provided).
Specific embodiment
For a further understanding of the present invention, the preferred embodiment of the invention is described below, but it is to be understood that thisA little descriptions are only further explanation the features and advantages of the present invention, rather than limiting to the claimed invention.
The preparation method of erythroblast simulation particle of the invention, first separation and Washed Red Blood Cells, obtain purifying red thinBorn of the same parents;Then purification of erythropoietin is added in dilution, load agent is added, the effect through impulse electric field imported into purifying for agent is loadedIn red blood cell, cell fixer is finally added into the cell being introduced into after loading agent, 18-28 DEG C of fixation washs cell, use cellIt saves liquid to save, obtains erythroblast simulation particle.
In above-mentioned technical proposal, red blood cell can be the red blood cell of people, be also possible to MCV value and the close mammal of peopleRed blood cell, with new blood preparation the present invention in analogies better effect.Separation method is by centrifugation, washing, filteringMode remove leucocyte and blood platelet in blood sample, wherein filtering can use leukocyte depletion filter remove leucocyte.
In above-mentioned technical proposal, the pH value of dilution is 7.1-7.5;Dilution is by ATP, MgCl2、KH2PO4、NaHCO3、Glucose and water composition;The concentration of ATP is 0.1%-1.0%;MgCl2Concentration be 0.1%-0.5%;KH2PO4Concentration is0.5%-3.0%;NaHCO3Concentration is 0.05%-0.3%;The concentration 0.01%-0.1% of glucose;General dilutedPurification of erythropoietin is to 1012-1014A/L.
In above-mentioned technical proposal, load agent be artificial synthesized RNA segment, load agent additive amount be greater than 1.5 μ g/L andWithin 3.0 μ g/L.It can be the 200- of arbitrary sequence to the sequence of artificial synthesized DNA or RNA segment without particular/special requirementThe segment of 1000bp;The expression vector selection being attached thereto uses pET-15b.Concretely: will be shown in sequence 1 or sequence 2DNA through expression vector is extracted and isolated and purified in artificial synthesized rear clone to pET-15b carrier, after amplification, most afterwards through digestionA large amount of DNA fragmentations are obtained after purification, i.e. load agent.
In above-mentioned technical proposal, load agent will be introduced into the process in purification of erythropoietin under the action of pulse electromagnetic fieldAre as follows: electroporation apparatus 90-120V voltage stimulates 4-8 seconds.
In above-mentioned technical proposal, the set time of fixer is 3-5h.
In above-mentioned technical proposal, cell fixer, cell-preservation liquid are used when carrying out carrying out washing treatment to red blood cell and productDetergent, be substance commonly used in the art, be not particularly limited.Wherein, detergent is conventional isotonic solution, including bufferingLiquid, preservative, inorganic salts and water, cell fixer include fixative, buffer, EDTA-2Na, preservative and water, can also be wrappedInclude nutriment;Wherein, fixative be one of formaldehyde, acetaldehyde, glutaraldehyde, paraformaldehyde, methanol, acetone or a variety of, oftenThe concentration of kind fixative is 0.1-2.0mL/L.Cell-preservation liquid includes buffer, nutritional ingredient, preservative and water.Above-mentioned technologyIn scheme, one of preservative Proclin-150, Proclin-200, Proclin-300 and Proclin-500 or twoKind;Buffer is PBS buffer solution, D-HANKS buffer, HEPES buffer solution, citrate buffer solution, sodium chloride buffer, boric acidOne of buffer is a variety of;Nutriment is glucose, mannitol, adenine etc..Commonly, detergent is by 20.0g/LDisodium hydrogen phosphate, 3.0g/L sodium dihydrogen phosphate, 5.5g/L sodium chloride, 0.2g/L Proclin-200 and 1L purified water composition;CarefullyBorn of the same parents' fixer is by 0.3-2.0mL/L acetaldehyde, 0.1-0.2mL/L glutaraldehyde, 2.0g/L sodium dihydrogen phosphate, 0.15g/L EDTA-2Na, 8.0g/L glucose, 2.5g/L adenine, 0.2g/LProclin-200 and 1L purified water composition;Cell-preservation liquid by0.2-0.5/L citric acid, 1.5-2.0g/L sodium citrate, 1.0g/L sodium dihydrogen phosphate, 8.0-15.0g/L glucose, 12.0g/LMannitol, 2.5g/L adenine, 0.3g/LProclin-200 and 1L purified water composition.
The present invention is further illustrated with reference to embodiments, and chemical reagent employed in embodiment is that analysis is pure, can be led toIt crosses commercially available.
Embodiment 1
The preparation method of erythroblast simulation particle: anticoagulant people's whole blood is placed in centrifuge, 3000rpm centrifugation10min removes supernatant, cleans sedimentation cell with detergent, and 3000rpm is centrifuged 10min, removes supernatant, washes repeatedly 2-3It is secondary, leucocyte-removing is removed with leukocyte depletion filter, obtains purification of erythropoietin.Purification of erythropoietin is diluted to 10 with dilution 112A/L,Load agent 1 is added according to 1.51 μ g/L, electroporation apparatus 100V voltage stimulates 5 seconds, into the purification of erythropoietin after electro photoluminescenceCell fixer 1 is added and fixes 3h at room temperature.It is washed repeatedly reaction product 3-4 times with detergent, with cell-preservation liquid 1 to productIt suspends, obtains Quality Control object.It is the blood cell analyzer of testing principle to above-mentioned Quality Control quality testing to nucleic acid fluorescent dyeingIt surveys, as a result (only provides erythroblast channel image) referring to fig. 2.
Load agent 1: by DNA shown in sequence 1 through being extracted in artificial synthesized rear clone to pET-15b carrier after amplificationAnd expression vector is isolated and purified, most obtain a large amount of DNA fragmentations after purification through digestion afterwards, i.e. load agent 1.
Detergent: 20.0g/L disodium hydrogen phosphate, 3.0g/L sodium dihydrogen phosphate, 5.5g/L sodium chloride, 0.2g/LProclin-200,1L purified water.
Dilution 1:1.0g/L magnesium chloride, 12.0g/L potassium dihydrogen phosphate, 1.2g/L sodium bicarbonate, 5.0g/LATP, 0.4g/L glucose, 1L purified water;PH value 7.2.
Cell fixer 1:2.0mL/L acetaldehyde, 0.1mL/L glutaraldehyde, 2.0g/L sodium dihydrogen phosphate, 0.15g/LEDTA-2Na, 8.0g/L glucose, 2.5g/L adenine, 0.2g/LProclin-200,1L purified water.
Cell-preservation liquid 1:0.2g/L citric acid, 1.5g/L sodium citrate, 1.0g/L sodium dihydrogen phosphate, 8.0g/L grapeSugar, 12.0g/L mannitol, 0.3g/LProclin-200,1L purified water.
Embodiment 2
The preparation method of erythroblast simulation particle: anticoagulant people's whole blood is placed in centrifuge, 3000rpm centrifugation10min removes supernatant, cleans sedimentation cell with detergent, and 3000rpm is centrifuged 10min, removes supernatant, washes repeatedly 2-3It is secondary, leucocyte-removing is removed with leukocyte depletion filter, obtains purification of erythropoietin.Purification of erythropoietin is diluted to 10 with dilution 212A/L,Load agent 2 is added according to 2.0 μ g/L, electroporation apparatus 100V voltage stimulates 8 seconds, adds into the purification of erythropoietin after electro photoluminescenceEnter cell fixer 2 and fixes 4h at room temperature.With detergent wash repeatedly reaction product 3-4 times, with cell-preservation liquid 2 to product intoRow suspends, and obtains Quality Control object.To blood cell analyzer that nucleic acid fluorescent dyeing is testing principle to above-mentioned Quality Control analyte detection,As a result referring to Fig. 3 (only providing erythroblast channel image).
Load agent 2: by DNA shown in sequence 2 through being extracted in artificial synthesized rear clone to pET-15b carrier after amplificationAnd expression vector is isolated and purified, most obtain a large amount of DNA fragmentations after purification through digestion afterwards, i.e. load agent 2.
Detergent: 20.0g/L disodium hydrogen phosphate, 3.0g/L sodium dihydrogen phosphate, 5.5g/L sodium chloride, 0.2g/LProclin-300,1L purified water.
Dilution 2:5.0g/L magnesium chloride, 12.0g/L potassium dihydrogen phosphate, 1.2g/L sodium bicarbonate, 8.0g/LATP, 0.6g/L glucose, 1L purified water;PH value 7.4.
Cell fixer 2:0.5mL/L formaldehyde, 0.1mL/L glutaraldehyde, 2.0g/L sodium dihydrogen phosphate, 0.15g/LEDTA-2Na, 0.2g/LProclin-500,1L purified water.
Cell-preservation liquid 2:0.5g/L citric acid, 2.0g/L sodium citrate, 1.0g/L sodium dihydrogen phosphate, 15.0g/L grapeSugar, 2.5g/L adenine, 0.3g/LProclin-300,1L purified water.
Embodiment 3
The preparation method of erythroblast simulation particle: selected people's anticoagulated whole blood is placed in centrifuge, 3000rpm fromHeart 10min removes supernatant, cleans sedimentation cell with detergent, and 3000rpm is centrifuged 10min, removes supernatant, repeated washing2-3 times, leucocyte-removing is removed with leukocyte depletion filter, obtains purification of erythropoietin.Purification of erythropoietin is diluted to 10 with dilution 312A/Load agent 1 is added according to 3.0 μ g/L in L, and electroporation apparatus 100V voltage stimulates 6 seconds, into the purification of erythropoietin after electro photoluminescenceCell fixer 3 is added and fixes 5h at room temperature.It is washed repeatedly reaction product 3-4 times with detergent, with cell-preservation liquid 3 to productIt suspends, obtains Quality Control object.It is the blood cell analyzer of testing principle to above-mentioned Quality Control quality testing to nucleic acid fluorescent dyeingIt surveys, as a result (only provides erythroblast channel image) referring to fig. 4.
Load agent 1: by DNA shown in sequence 1 through being extracted in artificial synthesized rear clone to pET-15b carrier after amplificationAnd expression vector is isolated and purified, most obtain a large amount of DNA fragmentations after purification through digestion afterwards, i.e. load agent 1.
Detergent: 20.0g/L disodium hydrogen phosphate, 3.0g/L sodium dihydrogen phosphate, 5.5g/L sodium chloride, 0.2g/LProclin-300,1L purified water.
Dilution 3:5.0g/L magnesium chloride, 11.5.0g/L potassium dihydrogen phosphate, 2.0g/L sodium bicarbonate, 10.0g/LATP,1.0g/L glucose, 1L purified water;PH value 7.5.
Cell fixer 3:0.3mL/L formaldehyde, 0.2mL/L glutaraldehyde, 2.0g/L sodium dihydrogen phosphate, 0.15g/LEDTA-2Na, 0.2g/LProclin-300,1L purified water.
Cell-preservation liquid 3:0.5g/L citric acid, 2.0g/L sodium citrate, 1.0g/L sodium dihydrogen phosphate, 15.0g/L grapeSugar, 0.3g/LProclin-300,1L purified water.
As attached drawing 1-4 as it can be seen that by erythroblast Quality Control object made from various embodiments of the present invention in blood analyserIt tests and analyzes, the simulation particle for not loading nucleic acid substances can not see the part of erythroblast on scatter plot, such as Fig. 1 instituteShow;And by electromagnetic pulse, treated, it can be seen that having obvious boundary with mature erythrocyte area, leucocyte area on scatter plotThe erythroblast area of limit, as shown in Figures 2 to 4.In summary, preparation method simple process of the invention, yield are high, suitableProduce in enormous quantities, erythroblast simulation particle obtained is as using fluorescence-scattered light method as the cellular blood of testing principle pointThe application of the Quality Control object of analyzer has good prospect.
The foregoing description of the disclosed embodiments enables those skilled in the art to implement or use the present invention.Various modifications to these embodiments will be readily apparent to those skilled in the art, as defined hereinGeneral Principle can be realized in other embodiments without departing from the spirit or scope of the present invention.Therefore, of the inventionIt is not intended to be limited to the embodiments shown herein, and is to fit to and the principles and novel features disclosed herein phase oneThe widest scope of cause.
Sequence table
<110>Di Rui medical science and technology limited liability company
<120>erythroblast simulation particle and the preparation method and application thereof
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 427
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
cttggaagag aggcgggtca aagaagtagt gaagaagcac tctcagttca taggctatcc 60
catcaccctt tatttgaaga aggagcgaga gaaggaaatt agtggtgatg aggcagagga 120
agagaaaggt gagaaagagg aggaagataa agatgatgaa gaaaagccca agatcgaaga 180
tgtgggttca gatgaggagg atgacagtgg taaggataag aagaagaaaa ctaagaagat 240
caaagagaaa tacattgatc aggaagagct aaacaagacc aagcctattt ggaccagaaa 300
ccctgatgac atcacccaag aggagtatgg agaattctat aagagcctca ccaatgactg 360
ggaagaccac ttggcagtca agcacttttc tgtagaaggt cagttggaat tcagggcatt 420
gctattc 427
<210> 2
<211> 800
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
atcgatagca ccctccagaa aatggtgctg acttccggct gtcaaatttt tctttctttc 60
ccagccacga cgaggtcgac agcatgagtt ctctaaagct ccagaagagg ctcgcagcct 120
ccgtgctgcg atgcggcaag aagaaggtct ggttggatcc caatgaaatc aacgagatcg 180
ccaacacaaa ctcgcgtcag aacatccgca agctcatcaa ggatggtctg atcatcaaga 240
agcccgtcgt ggtccactcc cgctaccgtg tgcgcaagaa caccgaggcc cgccgcaagg 300
gtcgtcactg cggattcgga aagcgcaagg gtactgcaaa cgcccgtatg cccaccaagc 360
tggtgtggat gcagcgccag cgcgttctgc gtcgcctgtt gaagaagtac cgcgacagca 420
agaagattga caggcacctg taccacgacc tgtacatgaa gtgcaagggt aacgtgttca 480
agaacaagcg cgtcctgatg gagtacatcc acaagaagaa ggctgagaag cagcgcagca 540
agatgctggc tgaccaagcc gaggctcgcc gacagaaggt gcgcgaggcc cgcaagcgcc 600
gcgaggagcg tatcgccacc aagaagcagg agctcattgc tctgcacgcc aaggaggacg 660
agatcgctgc caaggccgcc accgcgggtc actaagcagt ccggcctcgc tagtcgaggt 720
accccatatt gatagtactg tttatcatct gaataaaaca cctttggttt ggccgaaatg 780
attttgtaca aacgtgaaac 800

Claims (10)

CN201811264421.XA2018-10-292018-10-29Nucleated erythrocyte simulated particle and preparation method and application thereofActiveCN109459372B (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN201811264421.XACN109459372B (en)2018-10-292018-10-29Nucleated erythrocyte simulated particle and preparation method and application thereof

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN201811264421.XACN109459372B (en)2018-10-292018-10-29Nucleated erythrocyte simulated particle and preparation method and application thereof

Publications (2)

Publication NumberPublication Date
CN109459372Atrue CN109459372A (en)2019-03-12
CN109459372B CN109459372B (en)2021-03-26

Family

ID=65608683

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN201811264421.XAActiveCN109459372B (en)2018-10-292018-10-29Nucleated erythrocyte simulated particle and preparation method and application thereof

Country Status (1)

CountryLink
CN (1)CN109459372B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN112986065A (en)*2021-02-082021-06-18杭州同创医学检验实验室有限公司Whole blood quality control product for hematology analyzer and preparation method thereof
CN114964955A (en)*2022-05-102022-08-30桂林优利特医疗电子有限公司Nucleated red blood cell simulant and preparation method thereof
CN115372107A (en)*2021-05-212022-11-22深圳安侣医学科技有限公司 Pretreatment reagent and preparation method, cell staining method and pretreatment method
CN116097093A (en)*2020-09-032023-05-09生物辐射实验室股份有限公司Preparation of Nucleated RBC (NRBC) analogs for use as reference blood controls in automated blood analyzers

Citations (22)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6197593B1 (en)*1998-10-202001-03-06Coulter International Corp.Method for enumerating blood cells
US6399388B1 (en)*1999-08-202002-06-04Streck Laboratories, Inc.Hematology control and system for multi-parameter hematology measurements
US6653137B2 (en)*2001-12-032003-11-25Streck Laboratories Inc.Hematology reference control
US6723563B2 (en)*2001-12-032004-04-20Streck Laboratories Inc.Hematology reference control
WO2004085989A2 (en)*2003-03-202004-10-07Beckman Coulter, Inc.Dye compositions which provide enhanced differential fluorescence and light scatter characteristics
US20050136409A1 (en)*2003-12-192005-06-23Beckman Coulter, Inc.Hematology controls for reticulocytes and nucleated red blood cells
US20050266573A1 (en)*2003-10-022005-12-01Beckman Coulter, Inc.Reference control for optical measurement of nucleated red blood cells of a blood sample
US7109036B2 (en)*2004-05-132006-09-19Beckman Coulter, Inc.Hematology reference control containing an immature granulocyte component
US7135341B2 (en)*2004-04-072006-11-14Beckman Coulter, Inc.Reference control containing a nucleated red blood cell component
US7198953B2 (en)*2003-10-122007-04-03Beckman Coulter, Inc.Method of using a reference control composition for measurement of nucleated red blood cells
WO2005074522A3 (en)*2004-01-302007-10-04Univ CaliforniaDetection of ruminant dna via pcr
CN101122601A (en)*2007-09-242008-02-13孙艳萍Method for separating and authenticating erythroblast of blood
US20080113438A1 (en)*2006-11-142008-05-15Beckman Coulter, Inc.Hematology Linearity Control Composition, System and Method of Use
CN102109430A (en)*2009-12-252011-06-29深圳迈瑞生物医疗电子股份有限公司Nucleated red blood cell simulation particle and blood quality control substance and preparation methods and application thereof
CN104788563A (en)*2007-12-212015-07-22米迪缪尼有限公司Binding members for interleukin-4 receptor alpha (Il-4Ra) - 173
EP1694856B1 (en)*2003-11-042015-10-21Aviva Biosciences CorporationFiltration unit and method
CN105087470A (en)*2015-07-312015-11-25何静Method for separating and purifying human embryo trophoblast and placental mesenchymal stem cells
WO2016183482A1 (en)*2015-05-132016-11-17Rubius Therapeutics, Inc.Membrane-receiver complex therapeutics
WO2017177192A1 (en)*2016-04-072017-10-12The General Hospital CorporationWhite blood cell population dynamics
US20180140602A1 (en)*2015-04-072018-05-24Novartis AgCombination of chimeric antigen receptor therapy and amino pyrimidine derivatives
JP2018102289A (en)*2017-10-242018-07-05株式会社 TL GenomicsMethod for obtaining fetal cell chromosomal dnas
US10612096B2 (en)*2010-01-192020-04-07Verinata Health, Inc.Methods for determining fraction of fetal nucleic acids in maternal samples

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6197593B1 (en)*1998-10-202001-03-06Coulter International Corp.Method for enumerating blood cells
US6399388B1 (en)*1999-08-202002-06-04Streck Laboratories, Inc.Hematology control and system for multi-parameter hematology measurements
US6653137B2 (en)*2001-12-032003-11-25Streck Laboratories Inc.Hematology reference control
US6723563B2 (en)*2001-12-032004-04-20Streck Laboratories Inc.Hematology reference control
WO2004085989A2 (en)*2003-03-202004-10-07Beckman Coulter, Inc.Dye compositions which provide enhanced differential fluorescence and light scatter characteristics
US20050266573A1 (en)*2003-10-022005-12-01Beckman Coulter, Inc.Reference control for optical measurement of nucleated red blood cells of a blood sample
US7198953B2 (en)*2003-10-122007-04-03Beckman Coulter, Inc.Method of using a reference control composition for measurement of nucleated red blood cells
EP1694856B1 (en)*2003-11-042015-10-21Aviva Biosciences CorporationFiltration unit and method
US20050136409A1 (en)*2003-12-192005-06-23Beckman Coulter, Inc.Hematology controls for reticulocytes and nucleated red blood cells
WO2005074522A3 (en)*2004-01-302007-10-04Univ CaliforniaDetection of ruminant dna via pcr
US7135341B2 (en)*2004-04-072006-11-14Beckman Coulter, Inc.Reference control containing a nucleated red blood cell component
US7109036B2 (en)*2004-05-132006-09-19Beckman Coulter, Inc.Hematology reference control containing an immature granulocyte component
US20080113438A1 (en)*2006-11-142008-05-15Beckman Coulter, Inc.Hematology Linearity Control Composition, System and Method of Use
CN101122601A (en)*2007-09-242008-02-13孙艳萍Method for separating and authenticating erythroblast of blood
CN104788563A (en)*2007-12-212015-07-22米迪缪尼有限公司Binding members for interleukin-4 receptor alpha (Il-4Ra) - 173
CN102109430A (en)*2009-12-252011-06-29深圳迈瑞生物医疗电子股份有限公司Nucleated red blood cell simulation particle and blood quality control substance and preparation methods and application thereof
US20140099632A1 (en)*2009-12-252014-04-10Shenzhen Mindray Bio-Medical Electronics Co., Ltd.Preparation and use of nucleated red blood cell simulating particles and hematology control mixtures
US10612096B2 (en)*2010-01-192020-04-07Verinata Health, Inc.Methods for determining fraction of fetal nucleic acids in maternal samples
US20180140602A1 (en)*2015-04-072018-05-24Novartis AgCombination of chimeric antigen receptor therapy and amino pyrimidine derivatives
WO2016183482A1 (en)*2015-05-132016-11-17Rubius Therapeutics, Inc.Membrane-receiver complex therapeutics
CN105087470A (en)*2015-07-312015-11-25何静Method for separating and purifying human embryo trophoblast and placental mesenchymal stem cells
WO2017177192A1 (en)*2016-04-072017-10-12The General Hospital CorporationWhite blood cell population dynamics
JP2018102289A (en)*2017-10-242018-07-05株式会社 TL GenomicsMethod for obtaining fetal cell chromosomal dnas

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
QI SUN.ET: "Loss of the clock proteinPER2 shortensthe erythrocyte life span in mice", 《THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY》*
SUSAN G. LUND.ET: "THE EFFECTS OF CELL AGEING ON PROTEIN SYNTHESIS IN RAINBOW TROUT (ONCORHYNCHUS MYKISS) RED BLOOD CELLS", 《THE JOURNAL OF EXPERIMENTAL BIOLOGY》*
彭舸.ET: "外磁驱动轴流式血泵磁场分布及红细胞电磁特性分析", 《中国医学物理学杂志》*

Cited By (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN116097093A (en)*2020-09-032023-05-09生物辐射实验室股份有限公司Preparation of Nucleated RBC (NRBC) analogs for use as reference blood controls in automated blood analyzers
CN112986065A (en)*2021-02-082021-06-18杭州同创医学检验实验室有限公司Whole blood quality control product for hematology analyzer and preparation method thereof
CN112986065B (en)*2021-02-082021-08-31杭州同创医学检验实验室有限公司Whole blood quality control product for hematology analyzer and preparation method thereof
CN115372107A (en)*2021-05-212022-11-22深圳安侣医学科技有限公司 Pretreatment reagent and preparation method, cell staining method and pretreatment method
WO2022242398A1 (en)*2021-05-212022-11-24深圳安侣医学科技有限公司Pretreatment reagent, preparation method, cell staining method and pretreatment method
CN114964955A (en)*2022-05-102022-08-30桂林优利特医疗电子有限公司Nucleated red blood cell simulant and preparation method thereof

Also Published As

Publication numberPublication date
CN109459372B (en)2021-03-26

Similar Documents

PublicationPublication DateTitle
CN102109430B (en)Nucleated red blood cell simulation particle and blood quality control substance and preparation methods and application thereof
CN109459372A (en)Erythroblast simulation particle and the preparation method and application thereof
Arndt-Jovin et al.Studies of cellular differentiation by automated cell separation. Two model systems: Friend virus-transformed cells and Hydra attenuata.
JP2796325B2 (en) Method and reagent system for isolating, identifying and / or analyzing leukocytes from a whole blood sample
CN107076766B (en) Blood CRP quality control substance and its quality control method
CN101561443B (en)Five-classification leucocyte simulacrum particle, method for preparing same, and quality control substance and calibration substance containing same
KR101847225B1 (en)Method and system for analyzing a blood sample
JPH0379666B2 (en)
CA1319592C (en)Conservative whole blood sample preparation technique
JP2001091513A (en)Method for classifying and counting leukocyte
CN101881778A (en)Reticulocyte mimics and preparation method thereof
CN112305232A (en) Mixed quality control material of blood and specific protein and its quality control method
EP0867720B1 (en)Method of detecting hematopoietic progenitor cells
CN106950163A (en)The method of Flow cytometry Immune Organs of Chichen t lymphocyte subset group
Hübl et al.Measurement of absolute concentration and viability of CD34+ cells in cord blood and cord blood products using fluorescent beads and cyanine nucleic acid dyes
CN109142761B (en)Reticulocyte mimics and preparation method and application thereof
JPH0843378A (en)Method and equipment for magnetic cell measurement
JP2795746B2 (en) Methods and devices for screening cells or formers for a population exhibiting a selected property
CN112986589A (en)Reticulocyte mimic particle, platelet mimic particle preparation method and quality control material
JP6017845B2 (en) Method for detecting cells lacking GPI anchor protein
JP2004028615A (en)Method for detecting abnormality of lymphocyte subset
US3634290A (en)Method of preparing hemolysates for hemoglobin and other types of electrophoresis using chelating agents
CN119804877A (en) A method for detecting intracellular factors of T lymphocyte subtypes in rat spleen
Шалимов et al.Voronezh state Agricultural University named after Peter the Great, Voronezh, Russia BLOOD TESTS FOR DOGS WITH BABESIOSIS
SU1162875A1 (en)Method of determining amount of infusorians

Legal Events

DateCodeTitleDescription
PB01Publication
PB01Publication
SE01Entry into force of request for substantive examination
SE01Entry into force of request for substantive examination
GR01Patent grant
GR01Patent grant

[8]ページ先頭

©2009-2025 Movatter.jp